default author photo

Caigang Liu

China Medical University - Cancer Stem Cell and Translation Medicine Lab

SCHOLARLY PAPERS

2

DOWNLOADS

139

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Long-Term Efficacy and Safety of Anti-HER2 Antibody-Drug Conjugate SHR-A1811 in Heavily Treated HER2-Expressing or Mutated Advanced Solid Tumours: A Global Phase 1 Trial (HORIZON-X)

Number of pages: 36 Posted: 19 Aug 2025
Herui Yao, Min Yan, Zhongsheng Tong, Xinhong Wu, Yongmei Yin, Min-Hee Ryu, John J. Park, Shusuan Jiang, Jee Hyun Kim, Shouman Wang, Yahua Zhong, Mark Voskoboynik, Jian Zhang, Andreas Kaubisch, Caigang Liu, Yu Chen, Seock-Ah Im, Lingying Wu, Yingbin Liu, Vinod Ganju, Minal Barve, Hui Li, Guangyu Yao, Mudan Yang, Lequn Bao, Yiming Zhao, Jianli Zhao, Kaijing Zhao, Yu Shen, Shangyi Rong, Xiaoyu Zhu and Erwei Song
Sun Yat-sen University (SYSU), Zhengzhou University, Tianjin Medical University - Tianjin Cancer Institute, Huazhong University of Science and Technology, Nanjing Medical University, University of Ulsan - Asan Medical Center, Macquarie University, Central South University - Hunan Cancer Hospital, Seoul National University, Central South University, Wuhan University, Monash University, Fudan University - Department of Medical Oncology, Yeshiva University - Montefiore/Einstein Center for Cancer Care, China Medical University - Cancer Stem Cell and Translation Medicine Lab, Fujian Medical University - Fujian Cancer Hospital, Seoul National University - Department of Internal Medicine, Chinese Academy of Medical Sciences - National Cancer Center, Shanghai Jiao Tong University (SJTU), PASO Medical, Mary Crowley Cancer Research Center, Sichuan Cancer Hospital, Sun Yat-sen University (SYSU), Shanxi Cancer Hospital, Huazhong University of Science and Technology - Hubei Cancer Hospital, Sun Yat-sen University (SYSU), Sun Yat-sen University (SYSU), Jiangsu Hengrui Pharmaceuticals Co., Ltd., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Sun Yat-sen University (SYSU) - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation
Downloads 74 (844,901)

Abstract:

Loading...

antibody-drug conjugate, HER2-expressing or mutated advanced solid tumours, phase 1 trial, SHR-A1811

2.

Long-Term Outcomes by Neoadjuvant Efficacy Indexes in Patients with HR and HR /HER2 Breast Cancer after Neoadjuvant Systemic Therapy: A Systematic Review and Meta-Analysis

Number of pages: 22 Posted: 03 Oct 2022
Mingxin Liu, Zhan Zhang, Jiawen Bu, Xin-Bo Qiao, Lisha Sun, Qingtian Ma, Chao Liu, Nan M.D. Niu, Jinqi Xue, Guanglei Chen and Caigang Liu
China Medical University - Cancer Stem Cell and Translation Medicine Lab, China Medical University - Cancer Stem Cell and Translation Medicine Lab, China Medical University - Cancer Stem Cell and Translation Medicine Lab, China Medical University - Cancer Stem Cell and Translation Medicine Lab, China Medical University - Cancer Stem Cell and Translation Medicine Lab, China Medical University - Cancer Stem Cell and Translation Medicine Lab, China Medical University - Cancer Stem Cell and Translation Medicine Lab, China Medical University - Cancer Stem Cell and Translation Medicine Lab, China Medical University - Cancer Stem Cell and Translation Medicine Lab, China Medical University - Cancer Stem Cell and Translation Medicine Lab and China Medical University - Cancer Stem Cell and Translation Medicine Lab
Downloads 65 (933,592)

Abstract:

Loading...

breast cancer, hormone receptor positive, human epidermal growth factor receptor 2 positive, neoadjuvant efficacy indexes, prognosis